ADX40-Prostate cancer

Adjuvantix recently announced a strategic alliance with Pro-Cure Therapeutics Ltd based in York, targeted at the development of a vaccine for the treatment and prevention of prostate cancer.

There is strong evidence that cancer stem cells (CSCs) initiate cancers as well as leading to cancer spread and to recurrence after treatment. Pro-Cure, a cancer stem cell specialist, has successfully identified important new CSC derived targets that it believes will provide the foundation for the development of more effective cancer treatments.

The collaboration brings together Pro-Cure's proprietary CSC targets and expertise in prostate cancer with Adjuvantix's novel adjuvant technology and expertise in vaccine development. ADX40 is being used with Pro-Cure's novel prostate cancer antigens to determine the efficacy of prophylactic and therapeutic vaccination in preclinical models of prostate cancer.

Products